Navigation Links
Schering-Plough Announces Results of the Early ACS Trial
Date:3/30/2009

p>

No statistical difference was observed between the groups in either the primary or secondary endpoints. The primary endpoint occurred in 9.3 percent of the study group (receiving double-bolus plus infusion early administration of eptifibatide 12 or more hours prior to angiography), compared with 10.0 percent of the delayed provisional group (p=0.23). At 30 days, the death or (re)MI rate for the study group was 11.2 percent compared to 12.3 percent for the delayed provisional group (p=0.079).

Significantly higher rates of bleeding were observed in the study group, with 118 patients experiencing a TIMI major bleeding event, compared to 83 in the delayed provisional group (p=0.015). Investigators reported a 7.6 percent vs. 5.1 percent rate of moderate or severe bleeding (p<0.001) in the study group as compared to the delayed provisional group, as measured by the GUSTO scale. Red blood cell transfusions occurred in 8.6 percent of patients in the study group vs. 6.7 percent of patients in the delayed provisional group (p=0.001). There were no significant differences in mortality or any serious adverse events between the two groups.

"This was a very well-treated population that demonstrates the influence of aggressive and sophisticated therapies," said Dr. Newby. "Further evaluation of the safety and efficacy data at one year should provide additional insights into the early use of eptifibatide in this patient population."

Within the trial, the single largest group was PCI patients (n=5,559). An analysis of those randomized to receive early eptifibatide showed that these patients experienced fewer primary and secondary composite events after PCI than those randomized to the delayed provisional eptifibatide strategy.

"Consistent with findings from prior trials, in this double-bolus study, NSTE ACS patients undergoing PCI experienced fewer post-PCI ischemic complications with early eptifibat
'/>"/>

SOURCE Schering-Plough
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
2. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
3. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
4. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
5. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
6. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
7. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
8. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
9. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014 Decision Resources Group finds ... Memphis health system and hospital ... integration, with rivals Methodist Le Bonheur Healthcare and Baptist ... to coordinate patient care. In addition, a national contract ... most health plan enrollment in the Memphis ...
(Date:8/27/2014)... DALLAS , August 27, 2014 ... "Dental Equipment Market By Products (Dental Radiology, CAD/CAM, Dental Chairs, ... 2019" published by MarketsandMarkets, the global Dental Equipment Market ... from $5,416.3 million in 2014, growing at a ... Browse 95 market data tables and 61 ...
(Date:8/27/2014)... Aug. 27, 2014 By now, if you haven,t ... living on this planet. The awareness campaign has brought this ... helped to raise over $88.5 Million (and counting) for ALS. ... some companies are starting to as well. One ... Florida , who actually works with ALS sufferers and ...
Breaking Medicine Technology:Memphis-area Health Systems Turn Attention to Clinical Integration 2Dental Equipment Market Worth $7,138.9 Million by 2019 2Dental Equipment Market Worth $7,138.9 Million by 2019 3Acorn Stairlifts Gives a Lift to the ALS Ice Bucket Challenge 2
... 31, 2011 MultiCell Technologies, Inc. (OTC Bulletin Board: ... U.S. patent 7,935,528 by the United States Patent and Trademark ... liver stem cells to treat liver disease.  Under the terms ... is the worldwide exclusive licensee of U.S. patent 7,935,528.   ...
... Biotech Ltd. (NASDAQ: SVA ), a leading provider ... Mr. Kenneth Lee as a director to the Board of ... Xianping Wang who resigned from the Board due to personal ... SAIF Partners, a leading growth capital fund focused on China ...
Cached Medicine Technology:MultiCell Technologies is Granted Stem Cell Patent 2MultiCell Technologies is Granted Stem Cell Patent 3Sinovac Appoints Kenneth Lee to Board of Directors 2
(Date:8/27/2014)... (PRWEB) August 27, 2014 Beginning in September, ... Olympic Games (DOG) as an interactive, fun way for ... be free to all K9 Dog Park Doggy Daycare clients ... two days per week. Clients will be able to ... webcams. The dogs that compete in D.O.G. will win ...
(Date:8/27/2014)... one of the leading purveyors of real and synthetic hair wigs, ... all its products, for the coming Labor Day. , People searching ... hair products in two ways: when they spend more than ... code LABOR10; while when they spend more than $299, they can ... coupon code is needed when securely checkout, there are about 50 ...
(Date:8/27/2014)... new UCLA study has shown this is definitely the case ... how to treat their prostate cancer. , UCLA researchers found ... a much more difficult time making treatment decisions, called decisional ... their care and their long-term outcomes. , The study should ... the findings to target men less likely to know a ...
(Date:8/27/2014)... Aug. 27, 2014 Stroke patients are 70 per ... medications one year later if they have a prescription ... at St. Michael,s Hospital and the Institute for Clinical ... centres, researchers determined how many Ontarians were taking their ... having a stroke. The results reveal the importance of ...
(Date:8/27/2014)... There is an ... case of pancreatic cancer, one of the most aggressive types ... patients die within five years after the diagnosis. The KIT ... mortality rate. For preclinical and clinical tests of the agents, ... from investors. This will allow for the further development of ...
Breaking Medicine News(10 mins):Health News:K9 Dog Park Announces Launch Of Daycare Olympic Games – D.O.G. 2Health News:K9 Dog Park Announces Launch Of Daycare Olympic Games – D.O.G. 3Health News:K9 Dog Park Announces Launch Of Daycare Olympic Games – D.O.G. 4Health News:UniWigs Is Offering A Big Sale for Labor Day on All Its Products 2Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 2Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 3Health News:A prescription for better stroke care 2Health News:Preclinical development of tumor therapeutic agent starts 2
... integrate cardiovascular activity into their lives, such as walking, would ... the study researchers surveyed nearly 18,800 women, ages 70 to ... The data show women who walked for at least 1.5 ... than those who walked less than 40 minutes per week. ...
... chemotherapy improves survival and reduces the risk of recurrence in ... not spread beyond the ovary). ,About one quarter of ... when five-year survival is 85 percent. Most doctors may prefer ... 10 patients are adequately treated by surgery alone , thus ...
... be the healthiest environment for your child at bedtime. According ... may put children at risk for leukemia. Researchers have determined ... rhythm and suppress the production of melatonin. ,As an ... DNA from oxidative damage. Once damaged, DNA may mutate and ...
... says that Man's best friend might be able to detect ... can smell odors from malignant tumors in urine samples. ... over seven months to discriminate between urine from patients with ... was then given samples of urine from six control group ...
... Patients with diabetes, Crohn's disease, bowel cancer, constipation and ... medication orally instead of using injections.Scientists in India have ... deliver // drugs to manage diseases that often require ... ,The new gel can also prevent problems caused ...
... finds a cluster of risk factors known as metabolic ... of other risk factors. // ,Metabolic syndrome ... cardiovascular and coronary heart disease. Metabolic syndrome includes looking ... pressure.Metabolic syndrome has two different definitions including one by ...
Cached Medicine News:
... wide Mini-Sub cell GT system for ... acids in agarose gels includes a ... electrodes, a 15 x 7 cm ... two casting gates, and two 1.5 ...
... your data for future generations. Most gels can ... backing plate of our gel dryer, covering them ... over them to hold the cellophane flat. Tut's ... with an open area somewhat larger than the ...
... data for future generations. Most gels can be ... plate of our gel dryer, covering them with ... them to hold the cellophane flat. Tut's Tombs ... an open area somewhat larger than the gel ...
... Breeze Air Gel Dryer : Dry up to ... gels 8 10 cm without a vacuum ... drying, or no heat for controlled drying of ... dried gels. Add and remove gels at any ...
Medicine Products: